Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/15/2026
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Citi sees memory market undersupply worsening through 2031
- Global AI stocks fall as industry chiefs call for slowing development
- Enova drops bid to acquire Grasshopper Bancorp, reaffirms guidance
- Baldwin Group to go private in $7.7 billion deal with Sequence and Dell family office
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Edwards Lifesciences Reports First Quarter Results
April 26, 2016 4:15 PM EDTIRVINE, Calif., April 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2016.
First Quarter Highlights:
Sales grew 18.1% to $697.3 million, and underlying1 sales were up 19.7% THVT sales grew 37.0%, and underlying sales were up 38.3% GAAP EPS was $0.66, an increase of 17.9%, and adjusted2 EPS grew 24.6% to $0.71 2016 sales guidance raised to $2.7 - $3.0 billion from $2.6 - $2.85... More